* Applied Immune Sciences Inc., of Santa Clara, Calif.,said it was issued a U.S. patent for its technology thatenables removal of selected factors from whole blood orits components.
* Cypros Pharmaceutical Corp., of Carlsbad, Calif., saidit was issued a notice of allowance for a composition ofmatter patent covering a broad class of novel adenosinemetabolism inhibitors.
* Genta Jago, of San Diego and Muttenz, Switzerland,was issued a patent claiming additional configurations,compositions and manufacturing process for itsGeomatrix technology.
* Immunomedics Inc., of Morris Plains, N.J., wasawarded U.S. patent No. 5,439,665 claiming the use ofantibodies _ that bind to white blood cells accumulatingaround infectious and inflammatory lesions _ to delivera radioisotope to drug to the disease site.
* Isis Pharmaceuticals Inc., of Carlsbad, Calif., said itreceived notices of allowance for four patents. Two covernovel purine modifications used in antisenseoligonucleotide drugs. A third notice covers two chiralforms of ISIS 2105. The fourth covers a method for large-scale production of an intermediate used in antisenseoligonucleotide chemical synthesis.
* NeXstar Pharmaceuticals Inc., of Boulder, Colo., saidits wholly owned subsidiary, Vestar Inc., of San Dimas,Calif., was issued U.S. patent No. 5,435,989, whichdescribes the mechanism of action that enablesDaunoXome to preferentially accumulate in the region ofand within tumors.
* Scios Nova Inc., of Mountain View, Calif., was issuedU.S. patent No. 5,439,818 covering DNA molecules thatencode human basic fibroblast growth factor, expressionvectors containing the DNA and transformed cells ormicro-organisms containing the expression vectors.
* Sennes Drug Innovations Inc., of Houston, was issuedU.S. patent No. 5,424,400 covering the protein thatencodes the cell cycle inhibitor, SDI-1.
* Trimeris Inc., of Research Triangle Park, N.C., receiveda notice of allowance on composition of matter claims forT-20 _ an HIV inhibitor _ and related compounds.
* Vertex Pharmaceuticals Inc., of Cambridge, Mass., wasissued U.S. patent No. 5,439,939 covering the use of VX-366 to treat hemoglobin disorders.
* Xoma Corp., of Berkeley, Calif., said it was issued U.S.patent No. 5,439,807, which describes a method for therecombinant manufacture of bactericidal/permeability-increasing (BPI) proteins.
(c) 1997 American Health Consultants. All rights reserved.